Drugs in development · updated 13 November 2026
Zabalafin: clinical trials and development status
Other names and codes: AB-101
As of 13 November 2026 Zabalafin is in 3 active clinical trials (recruiting or ongoing, phases I–III) for 8 diseases. The most advanced phase is II.
Authorisation
- EU no (EMA)
- Italy not in the AIFA register
- Germany not available
- US no (FDA)
Sources: EMA, AIFA register (open data), FDA. For Germany only the EU centralised authorisation is shown: the national BfArM register is not one of our sources.
US-listed companies sponsoring active trials: Artiva Biotherapeutics, Inc. (Nasdaq: ARTV, 1 trial). Data from official sources, not financial advice.
Map of sites in Europe with recruitment status, every trial and an email when something changes. Full access free until 31 March 2027, no card needed.
What it is
A preparation of allogeneic, off-the-shelf natural killer (NK) cells, derived from umbilical cord blood (UCB) and ex vivo-expanded, that expresses a high-affinity variant of CD16, with potential immunostimulatory and antineoplastic activities. Upon administration, UCB-derived CD16-expressing NK cells AB-101 lyse tumor cells. NK cells AB-101 also secrete pro-inflammatory cytokines, which further stimulate an anti-tumor immune response. Upon coadministration with tumor-targeting monoclonal antibodies, the Fab moiety of the antibodies bind to the tumor-associated antigens (TAAs) expressed on tumor cells and the Fc moiety of the antibodies bind to CD16 expressed on NK cells AB-101. This leads to NK cell activation, cytokine secretion and antibody-dependent cellular cytotoxicity (ADCC). CD16, also known as Fc-gamma receptor III, is normally expressed on the surface of NK cells, neutrophils, monocytes and macrophages, and plays a key role in initiating ADCC. It is often downregulated in certain cancers, thereby inhibiting the anti-tumor immune response.
Diseases studied
For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.
| Disease | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Atopic dermatitis | II | 1 | NCT06855745 |
| Dermatitis | II | 1 | NCT06855745 |
| Eczema | II | 1 | NCT06855745 |
| Systemic lupus erythematosus | I | 2 | NCT06265220 |
| Granulomatosis with polyangiitis | I | 1 | NCT06581562 |
| Lupus nephritis | I | 1 | NCT06265220 |
| Pemphigus | I | 1 | NCT06581562 |
| Rheumatoid arthritis | I | 1 | NCT06581562 |
Everything on Zabalafin
In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.
Open in Phuturdex →Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 13 November 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, refers to the United States and is a Phuturdex calculation described on the Method page, not official data: the drug may already be marketed in other countries.